StreetInsider.com News Articles

Form SCHEDULE 13G Climb Bio, Inc. Filed by: FMR LLC

Wed, 08 Jul 2026 10:12:00 -0400

si-local-file:///var/storage/secattach/20260708/26745704.html

Form SCHEDULE 13G Climb Bio, Inc. Filed by: FMR LLC

Wed, 08 Jul 2026 10:12:00 -0400

si-local-file:///var/storage/secattach/20260708/26745704.html

Form SCHEDULE 13D/A Climb Bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Tue, 07 Jul 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260707/26742344.html

Form SCHEDULE 13D/A Climb Bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Tue, 07 Jul 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260707/26742344.html

Form 4 Climb Bio, Inc. For: Jun 29 Filed by: RA Capital Nexus Fund, L.P.

Wed, 01 Jul 2026 17:46:00 -0400

si-local-file:///var/storage/secattach/20260701/26722301.html

Form 4 Climb Bio, Inc. For: Jun 29 Filed by: RA Capital Nexus Fund, L.P.

Wed, 01 Jul 2026 17:46:00 -0400

si-local-file:///var/storage/secattach/20260701/26722301.html

Form 4 Climb Bio, Inc. For: Jun 29 Filed by: Celebi Breanna Maurine

Wed, 01 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260701/26721251.html

Form 4 Climb Bio, Inc. For: Jun 29 Filed by: Celebi Breanna Maurine

Wed, 01 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260701/26721251.html

Form 3 Climb Bio, Inc. For: Jun 29 Filed by: Celebi Breanna Maurine

Wed, 01 Jul 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260701/26721093.html

Form 3 Climb Bio, Inc. For: Jun 29 Filed by: Celebi Breanna Maurine

Wed, 01 Jul 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260701/26721093.html

Form 8-K Climb Bio, Inc. For: Jun 29

Wed, 01 Jul 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260701/26720873.html

Form 8-K Climb Bio, Inc. For: Jun 29

Wed, 01 Jul 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260701/26720873.html

Form 4 Climb Bio, Inc. For: Jun 27 Filed by: Brennan Aoife

Tue, 30 Jun 2026 19:51:00 -0400

si-local-file:///var/storage/secattach/20260630/26715206.html

Form 4 Climb Bio, Inc. For: Jun 27 Filed by: Brennan Aoife

Tue, 30 Jun 2026 19:51:00 -0400

si-local-file:///var/storage/secattach/20260630/26715206.html

Form 144 Climb Bio, Inc. Filed by: Brennan Aoife

Tue, 30 Jun 2026 19:50:00 -0400

si-local-file:///var/storage/secattach/20260630/26715204.html

Form 144 Climb Bio, Inc. Filed by: Brennan Aoife

Tue, 30 Jun 2026 19:50:00 -0400

si-local-file:///var/storage/secattach/20260630/26715204.html

H.C. Wainwright Reiterates Buy Rating on Climb Bio (CLYM)

Wed, 24 Jun 2026 06:44:43 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $20.00 price target on Climb Bio (NASDAQ: CLYM).

The analyst commented: "Budoprutug clinical data in idiopathic thrombocytopenic purpura underscores therapeutic potential. Climb Bio recently reported initial data from the ongoing Phase 1b portion of its Phase 1b/2a study evaluating budoprutug, an anti-CD19 monoclonal antibody, in adults with primary immune thrombocytopenia (ITP) demonstrating an encouraging safety and tolerability profile, robust B-cell depletion, and meaningful platelet responses in heavily pretreated patients. The initial data were presented at the European Hematology Association (EHA) Congress 2026, which was held on June 11-14, 2026, in Stockholm,

Form 8-K Climb Bio, Inc. For: Jun 11

Fri, 12 Jun 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260612/26641491.html

Form 8-K Climb Bio, Inc. For: Jun 11

Fri, 12 Jun 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260612/26641491.html

Form 424B5 Climb Bio, Inc.

Fri, 12 Jun 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260612/26641199.html

Form 424B5 Climb Bio, Inc.

Fri, 12 Jun 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260612/26641199.html

Climb Bio (CLYM) PT Raised to $20 at BTIG

Thu, 11 Jun 2026 12:07:22 -0400

BTIG analyst Julian Harrison raised the price target on Climb Bio (NASDAQ: CLYM) to $20.00 (from $19.00) while maintaining a Buy rating.

The analyst comments "Budoprutug (anti-CD19 mAb) delivered meaningful platelet responses in heavily pretreated adult ITP patients in initial Phase 1b data. In the 250mg cohort (n=6, median 38-week follow-up), B cells were depleted >90% by Week 4, mean platelet count rose 111K/µL at Week 24, and 4/6 patients achieved durable responses — including complete, durable responses in 2/4 rituximab-pretreated patients (platelets >100K/µL for 24+ weeks), supporting potential in a high-unmetneed refractory population. Safety was clean across both dose cohorts

Climb Bio (CLYM) PT Raised to $20 at BTIG

Thu, 11 Jun 2026 12:07:22 -0400

BTIG analyst Julian Harrison raised the price target on Climb Bio (NASDAQ: CLYM) to $20.00 (from $19.00) while maintaining a Buy rating.

Form 8-K Climb Bio, Inc. For: Jun 11

Thu, 11 Jun 2026 07:13:00 -0400

si-local-file:///var/storage/secattach/20260611/26632557.html

Form 8-K Climb Bio, Inc. For: Jun 11

Thu, 11 Jun 2026 07:13:00 -0400

si-local-file:///var/storage/secattach/20260611/26632557.html